Drug Trial Radar · NCT06713837
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
339
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Jan 2028
Study completion Jan 2028
Sponsor
- Lead sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hospital Vall d'Hebron; Cyprus Institute of Neurology and Genetics; European Leukemia Net; Fundacion Para La Investigacion Hospital La Fe; Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V.; Ospedale Pediatrico Bambin Gesù; Czech Lymphoma Study Group; Charite University, Berlin, Germany; Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León; University of Bologna; Hannover Medical School; German Society for Pediatric Oncology and Hematology GPOH gGmbH; Toscana Life Sciences Sviluppo s.r.l.; Lithuanian University of Health Sciences; Gruppo Italiano Malattie EMatologiche dell'Adulto; TIMELEX
- First posted
- Dec 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CANCER-01-03, Project ID 101104421)
Conditions
- Acute Myeloid Leukemia
- Relapse/Recurrence
Interventions
High intensity therapiesDrug
* High and intermediate dose Cytarabine * Mitoxantrone - Etoposide - Cytarabine (MEC) * fludarabine - cytarabine - idarubicin - G-CSF (FLAG-IDA) * cladribine - high dose cytarabine (2CDA+HDAraC) * mitoxantrone - intermediate dose cytarabine (MiDAC) * fludarabine - amsacrine - cytarabine (FLAMSA) * Mitoxantrone - Intermediate-dose Cytarabine (HAM) * 3+7 (cytarabine and daunorubicine or idarubicine)
Low intensity therapiesDrug
* Venetoclax+hypomethylating agent (decitabine, azacitidine) * Venetoclax+low dose cytarabine * Gilteritinib alone or in combination with low dose hypomethylating agent or low dose cytarabine * 2CDA 5mg/sqm + low dose cytarabine * Glasdegib+low dose cytarabine * Ivosidenib alone or in combination with low dose hypomethylating agent or low dose cytarabine * Single agent Gemtuzumab or Gemtuzumab in combination with alone or in combination with low dose hypomethylating agent or low dose cytarabine
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine in R/R AML patients the clinical benefit of low intensity therapy as shown by event-free survival compared to high intensity therapy.Time frame: 36 months
Locations
51 sites in 8 countries. Site status is shown where the registry gives one.
University Hospital Brno
Brno, Czechia · Recruiting
University Hospital Hradec Králové
Hradec Králové, Czechia · Not yet recruiting
University Hospital Olomouc
Olomouc, Czechia · Not yet recruiting
University Hospital in Ostrava
Ostrava, Czechia · Not yet recruiting
University Hospital in Pilsen
Pilsen, Czechia · Recruiting
Fakultní nemocnice Královské Vinohrady
Prague, Czechia · Recruiting
Uniklinik RWTH Aachen
Aachen, Germany · Recruiting
Universitätsmedizin Berlin Charité
Berlin, Germany · Not yet recruiting
University Hospital Cologne
Cologne, Germany · Not yet recruiting
University Hospital Greifswald
Greifswald, Germany · Recruiting
Krankenhaus St. Elisabeth und St. Barbara Halle (Saale) GmbH
Halle, Germany · Recruiting
University Hospital Halle
Halle, Germany · Recruiting
University Hospital of Rostock
Rostock, Germany · Recruiting
Heinrich-Braun-Klinikum gGmbH
Zwickau, Germany · Recruiting
Azienda Ospedaliero Universitaria Delle Marche
Ancona, Italy · Recruiting
ASST degli Spedali Civili
Brescia, Italy · Recruiting
ASST Valle Olonda
Busto Arsizio, Italy · Recruiting
Istituto Oncologico Veneto IRCCS
Castelfranco Veneto, Italy · Recruiting
AOU Careggi
Florence, Italy · Recruiting
IRST Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
Meldola, Italy · Recruiting
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, Italy · Recruiting
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy · Not yet recruiting
Azienda Ospedaliera di Rilievo Nazionale Antonio Cardarelli
Naples, Italy · Not yet recruiting
Azienda Ospedale-Università Padova
Padova, Italy · Recruiting
Fondazione IRCCS Policlinico San Matteo
Pavia, Italy · Not yet recruiting
Azienda Unita Sanitaria Locale Di Piacenza
Piacenza, Italy · Recruiting
Ospedale Infermi
Rimini, Italy · Recruiting
Casa Sollievo Della Sofferenza
San Giovanni Rotondo, Italy · Recruiting
Azienda Ospedaliero-Universitaria Senese
Siena, Italy · Recruiting
Ospedale San Bortolo
Vicenza, Italy · Recruiting
Policlinico Sant'Orsola
Bologna, BO, Italy · Recruiting
IRCCS Ospedale Policlinico San Martino
Genova, GE, Italy · Not yet recruiting
IRCCS Ospedale Policlinico San Martino
Genova, GE, Italy · Recruiting
Ospedali Riuniti Villa Sofia - Cervello
Palermo, PA, Italy · Recruiting
Ospedale S.Spirito - ASL Pescara
Pescara, PE, Italy · Not yet recruiting
Ospedale Santa Maria della Misericordia
Perugia, PG, Italy · Recruiting
Ospedale Santa Maria delle Croci
Ravenna, RA, Italy · Recruiting
Policlinico Tor Vergata
Roma, RM, Italy · Recruiting
Policlinico Umberto I
Roma, RM, Italy · Recruiting
AOU Città della Salute e della Scienza di Torino
Torino, TO, Italy · Recruiting
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.